Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Phase II placebo-controlled, double-blind study of selexipag in lumbar spinal stenosis with intermittent claudication
jRCT2080223810Phase 2Completed
- Sponsor
- Nippon Shinyaku
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in lumbar spinal stenosis (LSS) comparing Selexipag (NS-304) with Placebo (2 arms). Started Feb 2018; status: completed.
02
Drugs
selexipag
03
Conditions
lumbar spinal stenosis (LSS)
Beyond the preview
Go deeper on jRCT2080223810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223810.